Shandong Mingkang Industrial Park Management Co. , Ltd.

Heze City Development Investment (Group) Co. , Ltd. (hereinafter referred to as “Heze City Investment”) is a municipal-level state-owned enterprise, formerly known as Heze City Development Investment Co. , Ltd. , which was established in June 2017, the registered capital of 3 billion yuan is the main body authorized by the Municipal Party Committee and municipal government to engage in urban development, investment, construction and operation. After years of unremitting efforts, Heze City investment has grown into a city-owned backbone enterprise with 11 first-class Enterprises and 30 second-class enterprises with total assets of 30 billion yuan, he has won the honorary titles of provincial-level civilized unit and Heze as an advanced collective. Heze City Development Investment Co. , Ltd. is actively involved in the development of the pharmaceutical industry, following closely the development strategy of the Municipal Party Committee and the municipal government to build a “231” characteristic industrial system, to plan and invest in the project of“Incubator of API Innovation”. As a public production platform for apis and Advanced Pharmaceutical Intermediates, the project will open a channel between the domestic API research and development sector and the pharmaceutical production base in Heze, with the goal of introducing, incubating and accelerating the industrialization of API projects, it serves the excellent API R & D Companies in China. Located in the Juancheng Chemical Industrial Park, the project covers an area of about 453 mu with a total building capacity of about 280,000 square meters. Construction of Quality Inspection Research and Development Center, central tank area, public sewage treatment center, public pipe network and 24 sets of production units (each production unit includes production workshop, supporting warehouse and Power Workshop) , to build a professional, complete, standardized management of high-standard raw materials and advanced pharmaceutical intermediates public production base.